CStone Pharmaceuticals
Xia YANG (Sophia) is a seasoned professional with extensive experience in the pharmaceutical and financial sectors. Since 2021, Xia YANG has been serving as the Director of Investor Relations at 基石药业, focusing on investor communication, valuation modeling, and strategic analysis. Previously, Xia YANG held key positions at prominent companies such as Bristol Myers Squibb, AstraZeneca, and Pfizer, where responsibilities included market analysis, oncology strategy formulation, and evaluation of business development opportunities. Early career roles at UBS and PwC involved participation in IPOs, asset restructuring, and financial auditing. Xia YANG possesses a Master's degree in Biochemistry and Molecular Biology from Peking University, obtained in 2011.
This person is not in any teams
CStone Pharmaceuticals
CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established at the end of 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. With a strategic emphasis on immuno-oncology combination therapies, the Company has built an oncology-focused pipeline of 16 drug candidates, including 5 late-stage candidates at pivotal trials or registration stages. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone’s vision is to become a world-renowned biopharmaceutical company that is leading the way to conquering cancer.